Latest news
AIM ImmunoTech Reports Completion of Phase 2 Ampligen Dosing in Metastatic Pancreatic Cancer Trial, Advances Phase 3 Planning - Quiver QuantitativeQuiver Quantitative · Mon, 10 Aug 2026 12:47:00 GMTAIM ImmunoTech Reports Q2 2026: $9.9M Cash, $3.8M Net Loss - TradingViewTradingView · Mon, 10 Aug 2026 12:43:01 GMTTheriva Biologics Doses First Patient in VIRAGE2 Trial of VCN-01 for Metastatic Pancreatic Cancer - clinicaltrialvanguard.comclinicaltrialvanguard.com · Fri, 07 Aug 2026 06:44:00 GMTRevolution Medicines preps for pancreatic drug launch, boosting expected 2026 expenses - Endpoints NewsEndpoints News · Thu, 06 Aug 2026 01:31:00 GMTPancreatic cancer drug offers new hope for patients - KGWKGW · Tue, 04 Aug 2026 18:15:00 GMTLilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer - PR NewswirePR Newswire · Mon, 03 Aug 2026 11:45:00 GMT